GHK Matrikine Signaling & ECM Remodeling
GHK is a naturally occurring human plasma tripeptide that functions as a matrikine — a bioactive ECM-derived signaling fragment. Connectivity Map analysis indicates GHK modulates expression of over 4,000 human genes, including ECM synthesis, growth factor, anti-inflammatory, and stem cell pathways. Biotinoyl Tripeptide-1 is a biotin-conjugated derivative designed for improved stability and follicular delivery.
- Active ingredient
- GHK / Biotinoyl Tripeptide-1 (Biotin-GHK)
- Product
- Biotinoyl Tripeptide-1
- Evidence confidence
- Medium
Scope of the evidence
Strong evidence for the GHK parent peptide (five decades of research, multiple independent groups, CIR safety review). However, Biotinoyl Tripeptide-1 specifically has no independent peer-reviewed efficacy data — all evidence comes from Sederma’s proprietary technical files or multi-ingredient formulation studies. The biotin conjugate’s efficacy relies on the reasonable but unvalidated assumption that the GHK sequence retains signaling properties when copper coordination is replaced by biotin.
- Mechanistic detail
- GHK is a naturally occurring human plasma tripeptide first described in the early 1970s. Reported plasma concentrations decline with age, correlating with declining regenerative capacity [B25].
- GHK complexes with copper (II) ions with exceptionally high affinity (log K = 16.44), forming GHK-Cu. The complex is maximally bioactive, serving both as a gene-modulating matrikine and a safe copper delivery vector [B25].
- Connectivity Map data (Pickart & Margolina, 2018) indicates GHK modulates genes for ECM synthesis (collagen I/III, decorin), growth factors (VEGF, bFGF — up to 230% increase), anti-inflammatory pathways (NF-κB, TNF-α suppression), and stem cell maintenance (57 stem cell genes upregulated ≥50%). These findings were independently validated by Campbell et al. (2012) at Boston University [B26].
- Sederma’s ex vivo follicle culture data shows Biotinoyl Tripeptide-1 at 2 ppm increased follicular growth by 58% vs controls, comparable to minoxidil. At 5 ppm, growth was 121% greater than controls. This data is supplier-generated and has not been independently replicated.
- The biotin conjugation enhances stability (no copper-related oxidation or color), improves cosmetic compatibility, and may enhance follicular substantivity. However, it reduces the peptide’s copper-binding affinity, shifting the mechanism from copper delivery toward pure matrikine signaling.
- The widely cited claim that biotin “anchors” the peptide to fibronectin/laminin via avidin-like binding is not supported by evidence. The enhanced ECM integration observed clinically is attributable to GHK-mediated gene signaling that upregulates ECM protein synthesis, not a direct biochemical binding mechanism.
- Evidence gaps
- No independent peer-reviewed study tests Biotinoyl Tripeptide-1 as a monotherapy
- Clinical studies (Procapil) test a three-ingredient complex; individual contribution of the peptide cannot be isolated
- Pyo et al. (2007) — the most-cited hair follicle study — tested AHK-Cu (Ala-His-Lys), not GHK-Cu; these are structurally related but distinct
- No direct GHK-Cu monotherapy RCT for hair loss in humans
- Biotin-ECM “anchoring” mechanism is a marketing claim unsupported by physiological evidence
